# OnCo record afamitresgene-autoleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix owl: .
@prefix xsd: .
a schema:Drug ;
onco:kind "drug" ;
schema:identifier "afamitresgene-autoleucel" ;
schema:name "Afamitresgene autoleucel"@en ;
schema:description "Afamitresgene autoleucel was the first engineered T-cell receptor therapy approved for a solid tumour, synovial sarcoma."@en ;
schema:url ;
schema:dateModified "2026-09-04"^^xsd:date ;
schema:sameAs ;
owl:sameAs ;
schema:citation ;
onco:status "approved" ;
onco:modality "TCR-T (MAGE-A4)" ;
schema:alternateName "Tecelra" ;
onco:approval "US 2024: Advanced MAGE-A4+ synovial sarcoma, HLA-A*02+ (age ≥12 from 2026)" ;
onco:acceleratedApproval "US 2024-08-02: Treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices." ;
onco:related ;
onco:cancers , ;
onco:technologies ;
onco:targets , ;
onco:companies ;
onco:trials , ;
onco:keyPapers .